Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
暂无分享,去创建一个
Marc P. Bonaca | Deepak L. Bhatt | M. Sabatine | E. Braunwald | P. Steg | D. Angiolillo | R. Storey | F. Franchi | F. Rollini | J. Kuder | Mark R Thomas | Marc Cohen | H. Judge | Arif J Ahsan | R. Muthusamy | Francesco Franchi
[1] Jeroen J. Bax,et al. [2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]. , 2015, Kardiologia polska.
[2] D. Angiolillo,et al. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. , 2015, JACC. Cardiovascular interventions.
[3] Marc P. Bonaca,et al. Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.
[4] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[5] R. Brindis,et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.
[6] Marc P. Bonaca,et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. , 2014, American heart journal.
[7] R. Guieu,et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. , 2014, Journal of the American College of Cardiology.
[8] Deepak L. Bhatt,et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.
[9] Peter L Duffy,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.
[10] D. Atar,et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. , 2012, European heart journal.
[11] M. Cattaneo,et al. Abstract 213: Ticagrelor Inhibits Human Platelet Aggregation via Adenosine in Addition to P2Y12 Antagonism , 2012 .
[12] Jeroen J. Bax,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .
[13] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[14] C. Cannon,et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. , 2011, European heart journal.
[15] C. Cannon,et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. , 2010, Journal of the American College of Cardiology.
[16] Deepak L. Bhatt,et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.
[17] P. Gurbel,et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. , 2010, Journal of the American College of Cardiology.
[18] D. Kereiakes,et al. Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.
[19] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[20] M. Lordkipanidzé,et al. Response to aspirin in healthy individuals , 2009, Thrombosis and Haemostasis.
[21] E. Grove,et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. , 2008, Thrombosis research.
[22] Matthew J Price,et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.
[23] P. Gurbel,et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target , 2008, Platelets.
[24] P. Gurbel,et al. The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients , 2007, Diabetes.
[25] C. Cannon,et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. , 2007, Journal of the American College of Cardiology.
[26] C. Cannon,et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.
[27] P. Auquier,et al. Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events , 2007, Journal of thrombosis and haemostasis : JTH.
[28] D. Angiolillo,et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.
[29] P. Sandset,et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.
[30] E. Topol,et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.
[31] D. Angiolillo,et al. Novel antiplatelet agents in acute coronary syndrome , 2015, Nature Reviews Cardiology.
[32] Deepak L. Bhatt,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[33] K. Mahaffey,et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .
[34] Baris Gencer,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .
[35] N. Toma. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study. , 2010, Maedica.
[36] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi , 2004, The Canadian journal of cardiology.